A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients

This trial was a Phase 1, open-label, multicenter study of the pharmacokinetics (PK), pharmacodynamics (PD), and safety of a single dose of betrixaban in pediatric participants at risk of venous thromboembolism (VTE).

Start Date13 Jul 2018

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

[+1]

NCT03397888 / CompletedPhase 1

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Single center, prospective open label PK and PD study of betrixaban in subjects with mild and moderate hepatic impairment vs healthy volunteers.

Start Date16 Nov 2017

Sponsor / Collaborator

Portola Pharmaceuticals LLC

NCT02596100 / CompletedPhase 1

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

This is a single center open label randomized 4-period 2-sequence replicated crossover design study. A total of 52 healthy subjects will be randomized.

Start Date01 Sep 2015

Sponsor / Collaborator

Portola Pharmaceuticals LLC

100 Clinical Results associated with Betrixaban

100 Translational Medicine associated with Betrixaban

100 Patents (Medical) associated with Betrixaban

403

Literatures (Medical) associated with Betrixaban

01 Nov 2024·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period

Article

Author: Moyer, Eric ; Gottlieb, Michael ; Bernard, Kyle

INTRODUCTION:

Pulmonary embolism (PE) is a major cause of morbidity and mortality in the United States. However, as diagnostic imaging, risk stratification tools, and treatment have evolved over time, there is a critical need for current data on the incidence, testing, admission rates, and medical management of PE in the ED setting.

METHODS:

This was a cross-sectional study of ED patients with PE diagnoses from 1/1/2016 to 12/31/2023 using the Epic Cosmos national database. ED visits were identified using ICD-10 codes corresponding to acute PE. Chronic PEs were excluded. Outcomes included total ED visits, admission rates, anticoagulant treatment prescribed from the ED, and thrombolytic therapy. Anticoagulant prescriptions included warfarin, enoxaparin, dabigatran, apixaban, rivaroxaban, edoxaban, and betrixaban. Thrombolytic agents included alteplase, tenecteplase, and urokinase. We also assessed changes in the overall rate of CT pulmonary angiograms (CTPA) performed.

RESULTS:

Out of 186,138,130 total ED encounters, PE represented 531,968 (0.29 %). The overall rate of PE diagnosis rose slowly from 0.20 % in 2016 to a peak of 0.35 % in 2021. Among those with PE, 363,584 (68.3 %) were admitted. The rate of admission declined over time from 75.6 % to 66.1 %. Among those prescribed anticoagulation, the most common medication was apixaban (40.0 %), followed by rivaroxaban (17.3 %), enoxaparin (6.1 %), warfarin (2.6 %), and dabigatran (0.4 %). Thrombolytics were administered in 4.5 % of cases, with the rate of thrombolytics peaking at 5.3 % in 2018 before lowering to 3.5 % in 2023. The overall rate of CTPA increased from 2.4 % to 5.0 %, while the rate of proportion of PEs diagnosed declined from 8.7 % to 6.4 %.

CONCLUSION:

This study highlights significant shifts in the epidemiology and management of PE within the ED setting. Overall rates of PE rose, while a larger proportion were discharged. Direct oral anticoagulants have become the predominant therapy with the majority of patients receiving apixaban. Thrombolytic use occurs in a small subset and has been declining over time. CTPA rates have risen, while the overall diagnostic yield has declined.

01 Oct 2024·NEUROTOXICITY RESEARCH

Pharmacology of Adenosine A1 Receptor Agonist in a Humanized Esterase Mouse Seizure Model Following Soman Intoxication

Article

Author: Acon-Chen, Cindy ; Shih, Tsung-Ming ; Munoz, Crystal ; Keith, Zora-Maya

Abstract:

Recently a novel genetically modified mouse strain with serum carboxylesterase knocked-out and the human acetylcholinesterase gene knocked-in (KIKO) was created to simulate human responses to nerve agent (NA) exposure and its standard medical treatment. A1 adenosine receptor (A1AR) agonist N-bicyclo-(2.2.1)-hept-2-yl-5'-chloro-5'-deoxyadenosine (ENBA) alone is a potent anticonvulsant and neuroprotectant (A/N) in both rat and KIKO mouse soman (GD) seizure models. In this study we utilized the KIKO mouse to evaluate further the basic pharmacologic A/N effects of ENBA as an adjunct to standard NA medical treatments (i.e., atropine sulfate, pralidoxime chloride [2-PAM], and midazolam). Male mice, implanted with cortical electroencephalographic (EEG) electrodes, were pretreated with asoxime (HI-6) and exposed to an epileptogenic dose of GD (33 µg/kg, s.c.) or saline (sham exposure) and then treated 15 min after seizure onset with ENBA at 15 mg/kg, i.p. (a minimum efficacy dose in suppressing NA-induced seizure) alone or as an adjunct to standard medical treatments. We collected EEG activity, seizure suppression outcomes, daily body temperature and weight, heart rate, toxic signs, neuropathology, and lethality data for up to 14 days. Without ENBA, death from NA exposure was 45%, while with ENBA, either alone or in combination with midazolam, the survival improved to 80% and 90%, respectively. Additionally, seizure was suppressed quickly and permanently, toxic signs, hypothermia, and bradycardia recovered by 48 h, and no neuropathology was evident. Our findings confirmed that ENBA is a potent A/N adjunct for delayed medical treatments of NA exposure.

01 Sep 2024·BRITISH JOURNAL OF PHARMACOLOGY

Pharmacological inhibition of STING reduces neuroinflammation‐mediated damage post‐traumatic brain injury

Article

Author: Fryer, Amelia L. ; Jobling, Andrew ; Moore, Zachery ; Wong, Bruce X. ; Crack, Peter J. ; Mobilio, Frank ; Abdullah, Amar ; Zheng, Gang ; Taylor, Juliet M. ; de Veer, Michael

Background and Purpose:

Traumatic brain injury (TBI) remains a major public health concern worldwide with unmet effective treatment. Stimulator of interferon genes (STING) and its downstream type‐I interferon (IFN) signalling are now appreciated to be involved in TBI pathogenesis. Compelling evidence have shown that STING and type‐I IFNs are key in mediating the detrimental neuroinflammatory response after TBI. Therefore, pharmacological inhibition of STING presents a viable therapeutic opportunity in combating the detrimental neuroinflammatory response after TBI.

Experimental Approach:

This study investigated the neuroprotective effects of the small‐molecule STING inhibitor n‐(4‐iodophenyl)‐5‐nitrofuran‐2‐carboxamide (C‐176) in the controlled cortical impact mouse model of TBI in 10‐ to 12‐week‐old male mice. Thirty minutes post‐controlled cortical impact surgery, a single 750‐nmol dose of C‐176 or saline (vehicle) was administered intravenously. Analysis was conducted 2 h and 24 h post‐TBI.

Key Results:

Mice administered C‐176 had significantly smaller cortical lesion area when compared to vehicle‐treated mice 24 h post‐TBI. Quantitative temporal gait analysis conducted using DigiGait™ showed C‐176 administration attenuated TBI‐induced impairments in gait symmetry, stride frequency and forelimb stance width. C‐176‐treated mice displayed a significant reduction in striatal gene expression of pro‐inflammatory cytokines Tnf‐α, Il‐1β and Cxcl10 compared to their vehicle‐treated counterparts 2 h post‐TBI.

Conclusion and Implications:

This study demonstrates the neuroprotective activity of C‐176 in ameliorating acute neuroinflammation and preventing white matter neurodegeneration post‐TBI. This study highlights the therapeutic potential of small‐molecule inhibitors targeting STING for the treatment of trauma‐induced inflammation and neuroprotective potential.

News (Medical) associated with Betrixaban

17 Jan 2024

·pipelinereview.com

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

SAN DIEGO, CA, USA I January 17, 2024 I Tr1X, Inc. today announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. The financing was led by Bay Area-based The Column Group, with participation from NEVA SGR and Alexandria Ventures. The Company appointed William Lis Chief Executive Officer, strengthened its leadership team with other biopharma industry veterans, and announced members of the Board of Directors and Scientific Advisory Board. "We are thrilled to partner with Bill Lis, Maria Grazia Roncarolo and Tr1X's world-class team to revolutionize the field through its innovative, breakthrough science," said Leon Chen, Ph.D., MBA, Partner at The Column Group and Tr1X Board Member. "With its experienced management team at the helm, we are confident in Tr1X's ability to bring curative cell therapies to patients who currently require life-long treatment and management." Science and Pipeline The Company's science is primarily based on the work of Tr1X's Scientific Founder Maria Grazia Roncarolo, M.D., the discoverer of Type 1 regulatory T (Tr1) cells, which have features that can benefit patients with autoimmune and inflammatory diseases. Tr1 cells, a differentiated subpopulation of regulatory T cells, are crucial for maintaining homeostasis and tolerance in healthy individuals and have several important functions. These include dampening of local inflammation and downregulation of the inflammasome, suppression of pathogenic effector T cell responses, and induction of long-term tolerance as observed in preclinical models and patients. Tr1X's proprietary technology enables the conversion of CD4 + T cells isolated from healthy donors into Treg-like cells that have a similar function and profile to naturally occurring Tr1 cells. These cells can be further engineered to target specific tissues or organs to enable local, targeted immunomodulation. With a proprietary, GMP-grade, closed-loop system that provides consistency, quality and reliability at scale, Tr1X can enable production of its products at commercial volume. Currently, Tr1X is working on its first investigational Tr1 cell therapy, TRX103, which it plans to evaluate in a Phase 1 trial to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant. The Company is developing additional pipeline programs to treat inflammatory bowel disease, Type 1 diabetes and multiple B-cell mediated autoimmune diseases. "The ability to develop a pipeline of medicines based on our work on regulatory T cells represents the culmination of decades of discovery and research into the underpinnings of immunological tolerance and autoimmunity," said Dr. Roncarolo, Scientific Founder, President and Head of R&D at Tr1X. "Tr1 cells have unique properties and represent the ideal therapeutic platform from which to develop 'immune reset' products. Our two platforms have the required attributes to address a broad set of indications, including dual targeting of pathogenic T and B cells. These engineered cells have the potential to induce tolerance, which could transform the lives of people living with chronic autoimmune diseases by providing them with a cure instead of ongoing treatment." Proven Leadership Team, Board of Directors and Scientific Advisory Board Tr1X is led by industry veterans with cell therapy expertise who have a track record of discovery, development and commercialization of more than a dozen novel first- or best-in-class medicines. Chief Executive Officer William "Bill" Lis has more than 25 years of biotech executive leadership experience in building companies and product pipelines from R&D stage through commercialization. He most recently served as Chairman and interim CEO of Jasper Therapeutics, Inc., from 2019 to 2022, where he led the company's Series A and follow-on financings and successful brequilimab Phase 1 study readouts in hematopoietic stem cell transplantation. Before that, he served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2008 to 2018 after serving as Chief Operating Officer, where he built the company from a private research-stage startup into a multi-billion dollar public company that launched Andexxa ® and Bevyxxa ® . Portola was acquired by Alexion Pharmaceuticals, Inc. in 2020. Previously, Mr. Lis held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as Senior Vice President of New Product Development and Business Development, leading in-licensing efforts, development and commercial P&L operations for Xarelto ® and the company's therapeutics pipeline. Earlier in his career, he held positions at Millennium Pharmaceuticals, Inc., COR Therapeutics, Inc. and Rhone Poulenc Rorer. He is a director of Zai Laboratories, Inc. Scientific Founder, President and Head of R&D Dr. Maria Grazia Roncarolo is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and Medicine, Founder of the Center for Definitive and Curative Medicine, and former Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated diseases and regenerative medicine into novel patient therapies. She and her team were the first to discover Type 1 regulatory T cells in patients and the first to develop curative treatments for ADA-SCID. A pediatric immunologist by training, she was instrumental in bringing novel cell and gene therapies to market, including Strimvelis ® and Libmeldy ® . She is a Co-Founder of the gene-editing companies Graphite Bio and Kamau Therapeutics. Co-Founder and Chief Operating Officer David de Vries has over a decade of experience founding and scaling companies at the intersection of healthcare, biology and technology. Prior to Tr1X, he was Co-Founder and Chief Operating Officer of Arine, a medication intelligence and therapeutic optimization company he helped start, launch and scale to serve millions of patients, working with some of the largest healthcare organizations in the U.S. Previously, he worked at Proteus Digital Health, an innovative drug-device company and the first in the field to obtain FDA approval for a digital medicine, Abilify MyCite ® . "Tr1X is committed to bringing cures to millions of patients suffering from autoimmune diseases through our scalable, universal allogeneic cell therapy process that has been demonstrated to yield billions of cells in a single run," said Mr. Lis, CEO of Tr1X. "In just 18 months, the Tr1X team has successfully closed a Series A financing and extension, assembled an experienced leadership team, board of directors and scientific advisory board, and established a scalable GMP-grade manufacturing process. We are well positioned to advance our pipeline of first-of-their kind allogeneic engineered Treg and CAR-Treg cell therapies that have the potential to address the significant limitations of current cell therapies for autoimmune diseases, which include, among others, poor trafficking, lack of stability, limited persistence and induction of cytokine-associated toxicities, at a fraction of the cost per dose." In addition to Mr. Lis, Dr. Roncarolo and Mr. de Vries, the Tr1X leadership team includes Xavier Paliard, Pharm.D., Ph.D., Chief Scientific Officer; James Adams, MBA, Chief Technical Officer; Jonathan Perrin, J.D., Co-Founder and General Counsel; and Erik Poulsen, M.S., Head of Regulatory Affairs. Joining Mr. Lis and Dr. Roncarolo on Tr1X's Board of Directors are: Tr1X has recruited experts in immunology, stem cell and gene therapy, T-cell biology and immune-mediated diseases to join its Scientific Advisory Board. They include: About Tr1X Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, including the scientists behind the discovery of Tr1 cells, the company's pipeline of universal allogeneic cell therapies is being developed for diseases with high unmet medical need. The company is headquartered in San Diego, has developed a robust intellectual property portfolio, and is backed by leading investors, including The Column Group, NEVA SGR and Alexandria Ventures. For more information visit: www.tr1x.bio . SOURCE: Tr1X

Cell TherapyExecutive ChangePhase 1ImmunotherapyGene Therapy

25 Sep 2023

·www.biospace.com

Jasper Therapeutics Appoints Herb Cross as Chief Financial OfficerJeet Mahal Continues as COO

REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimens, today announced the appointment of Herb Cross, an experienced senior financial executive, as the company’s Chief Financial Officer (CFO). Jeet Mahal, who previously held both CFO and Chief Operating Officer (COO) roles, will continue as the company’s COO. “We are very pleased to welcome Herb, who brings more than twenty years of public company executive leadership experience to our team, as our new CFO,” said Ronald Martell, Chief Executive Officer of Jasper. “With multiple clinical studies of briquilimab in Chronic Spontaneous Urticaria, Low to Intermediate Risk MDS and hematopoietic stem cell transplant either ongoing or planned to start this year, we are taking the opportunity to strengthen our leadership team in preparation for continued growth. The addition of Herb also allows Jeet Mahal to focus on our increasing operational needs in his ongoing role as our COO.” "I am excited to join Jasper at an important time in its development, particularly given the growing set of compelling data supporting the continued development of briquilimab,” said Herb Cross. “I look forward to building on the company’s strong foundation and am eager to begin working with the leadership team to help realize briquilimab’s potential.” Mr. Cross brings more than two decades of experience in financial leadership roles at both public and private biotechnology companies. Before joining Jasper, he served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr. Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals and was CFO at Affymax as well. Mr. Cross began his career at Arthur Andersen, LLP, and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California. Mr. Mahal joined Jasper in December 2019 from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in Portola Pharmaceuticals’ equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics. Inducement Grant In connection with the appointment of Mr. Cross as its Chief Financial Officer, on September 22, 2023, Jasper granted Mr. Cross an option to purchase 550,000 shares of its voting common stock (the “Option”). The Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to Mr. Cross’ employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option is $0.78. The Option will vest over four years, with 25% of the total number of shares vesting on September 22, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Cross’ continued service to Jasper on each vesting date. Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety pro over 145 dosed patients and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. For more information, please visit us at . Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, LR-MDS and stem cell transplant conditioning and plans to commence multiple clinical studies of briquilimab, briquilimab’s further development and the strategic direction for briquilimab. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: John Mullaly (investors) LifeSci Advisors 617-429-3548 jmullaly@lifesciadvisors.com Jeet Mahal (investors) Jasper Therapeutics 650-549-1403 jmahal@jaspertherapeutics.com Lauren Barbiero (media) Real Chemistry 646-564-2156 lbarbiero@realchemistry.com

Executive Change

100 Deals associated with Betrixaban

External Link

KEGG	Wiki	ATC	Drug Bank
D08873	Betrixaban	B01AF	DB12364

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Venous Thromboembolism	US	Portola Pharmaceuticals LLC	23 Jun 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Phase 2	US	Portola Pharmaceuticals LLC	06 Aug 2015
Atrial Flutter	Phase 2	-	Portola Pharmaceuticals LLC	01 Sep 2010
Atrial Fibrillation	Phase 2	US	Portola Pharmaceuticals LLC	01 Oct 2008
Atrial Fibrillation	Phase 2	CA	Portola Pharmaceuticals LLC	01 Oct 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03346083 (CTgov)	Phase 1	Venous Thromboembolism	21	Betrixaban (Cohort 1: Betrixaban 40 mg)	skvqxapudv(lzbmtxqlph) = nsjczusako pngdhcdnlz (ohlhvotqel, mbhonpncsb - bduejntxcp) View more	-	12 Jan 2024
				Betrixaban (Cohort 2: Betrixaban 80 mg)	skvqxapudv(lzbmtxqlph) = vrqinjencw pngdhcdnlz (ohlhvotqel, rcsupzwclq - qmujwqnkro) View more
NCT03330457 (CTgov)	Phase 2	Hemorrhage	18	Andexanet alfa (bolus)+Betrixaban 80 mg PO QD (Cohort 1 Bertrixaban/Andexanet)	corjhbkpnz(jixmaezsvi) = zogicacrkg zddkzwhnkj (hmjgosvmlg, quuvbddpok - dvbnexvqpu) View more	-	19 Aug 2020
				Andexanet alfa (bolus)+Betrixaban 80 mg PO QD (Cohort 1 Bertrixaban/Placebo)	corjhbkpnz(jixmaezsvi) = fsvjukwwdp zddkzwhnkj (hmjgosvmlg, auagkmiwie - slhtvgldeb) View more
NCT02111564 \| NCT00571649 \| NCT01583218 (Pubmed)	Phase 3	Acute Disease	-	Betrixaban or Rivaroxaban	abgifdujui(gfpzsibarf) = xsuvwvnepa uuqqdnfvwq (mfexulfczc, -2.32% - -0.69%) View more	-	09 Jul 2020
ISTH2019	Not Applicable	-	-	Apixaban	dukdanxxpq(icoeazayfr) = wqwqlyyrvk fgsajvurza (fjmoedrvxb ) View more	-	10 Jun 2019
				Betrixaban	dukdanxxpq(icoeazayfr) = zrfowwwrdy fgsajvurza (fjmoedrvxb ) View more
NCT01583218 (APEX, Pubmed \| Intensive Care Med)	Phase 3	Critical Illness	7,513	Betrixaban	yosdfzznhe(scbydbtgpf) = zngqefugxe ydswkveyqu (wnxalfoufb ) View more	-	01 Apr 2019
				Enoxaparin	yosdfzznhe(scbydbtgpf) = ltbvbclclf ydswkveyqu (wnxalfoufb ) View more
APEX trial (ESC2018)	Not Applicable	Venous Thromboembolism	703	Betrixaban	rfjurftqmi(mhmuryrltt) = xqxtdohkdz pkiaeacprf (qlwdayzzln )	-	27 Aug 2018
				Enoxaparin	rfjurftqmi(mhmuryrltt) = jbwqmngaok pkiaeacprf (qlwdayzzln )
NCT01583218 (APEX, Pubmed)	Phase 3	Venous Thromboembolism	7,513	Betrixaban	pbofqstrof(kcqrqdiaji) = jubhhmnpfv uivzruuxyf (rlpmogqirq )	Positive	01 Jan 2018
				Enoxaparin	pbofqstrof(kcqrqdiaji) = isipadlpre uivzruuxyf (rlpmogqirq )
NCT00375609 (CTgov)	Phase 2	Thromboembolism	215	Betrixaban (Betrixaban 15 mg)	nrfehxkrpm(zkqorgjyrr) = heujxcmyta hwfuyrrpng (kjxvngzljy, eexqnssean - mveieztnzd) View more	-	15 Dec 2017
				Betrixaban (Betrixaban 40 mg)	nrfehxkrpm(zkqorgjyrr) = pacpoeiqgg hwfuyrrpng (kjxvngzljy, iepmkwdnmk - xpdyzazqgc) View more
NCT00742859 (EXPLORE-Xa, CTgov)	Phase 2	Atrial Fibrillation	508	Betrixaban (Betrixaban 40 mg)	dgiepmceqi(fhwzkmbyak) = eywjygkpce blgorostyn (bslzsutsmu, rgnhjvibtf - jnexmryazf) View more	-	26 Sep 2017
				Betrixaban (Betrixaban 60 mg)	dgiepmceqi(fhwzkmbyak) = xuxcwrssnm blgorostyn (bslzsutsmu, hbrhxcmqad - mjmerovslc) View more
NCT01583218 (APEX Trial \| APEX, CTgov)	Phase 3	Venous Thromboembolism	7,513	Betrixaban (Betrixaban)	kjxjgstuof(brdedxczat) = jgewaedodw vlrlqcvvtp (xkibsukzzo, zxclctsowx - caqukasgeq) View more	-	20 Sep 2017
				Enoxaparin (Enoxaparin)	kjxjgstuof(brdedxczat) = iieqnkljbb vlrlqcvvtp (xkibsukzzo, gxtgbgxvoi - lndgusqypv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis